Furthermore, the treatment with a high-affinity monoclonal antibody (infliximab) to TNF-α, diminishes the expression of PAD4 and TNF-α-driven NETosis in UC [46], suggesting that infliximab could also be used as a potential therapy targeting NETs in CRC. This evidence concerns the gene TNF and colorectal carcinoma.